ReviewClinical reviews in allergy & immunology2019
Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA.
Review in Clinical reviews in allergy & immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Application of Different Ventilation Modes Combined with AutoFlow Technology in Thoracic Surgery.Journal of healthcare engineering · 2022Trial
- Landscape of Aeroallergen Sensitization in Asia.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Review
- A novel recognition of the major allergen, Hum j 1, fromThe World Allergy Organization journal · 2025Article
- Characterization of the clinical relevance and hypoallergenic peptides of the newly evidenced major allergen Hum j 1.Frontiers in immunology · 2025Article
- Sensitization profiles to house dust mite Dermatophagoides pteronyssinus molecular allergens in the Lithuanian population: Understanding allergic sensitization patterns.Clinical and translational allergy · 2024Article
- Safety of subcutaneous immunotherapy with Novo-Helisen-Depot in the children: a retrospective analysis from a single center in Northern China.Frontiers in pediatrics · 2024Article
- Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens.Immunotherapy · 2024Review
- Allergen immunotherapy in China.Frontiers in allergy · 2023Review
- Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.Allergy, asthma & immunology research · 2022Review
- Prevalence of Sensitization to Aeroallergens in Greater Beijing Region Children With Respiratory Allergy.Frontiers in pediatrics · 2022Article
- Review
- Prevalence of and risk factors for asthma among people aged 45 and older in China: a cross-sectional study.BMC pulmonary medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Allergen immunotherapy (AIT) for allergic rhinitis (AR), asthma, and other allergic diseases has developed quickly. House dust mite (HDM), Artemisia (wormwood), Humulus japonicus (Japanese hop), Alternaria alternata, and Cladosporium herbarum are the five most common inhalant allergens in China. AIT has been performed in China for over 60 years. With the support of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA), the Chinese College of Allergy and Asthma (CCAA) was established in 2016 as a specialized branch of CDMA and is the main certification authority for AIT. Chinese allergists and scientists have made tremendous progress in the development of AIT. There have been many publications by Chinese allergists and scientists worldwide encompassing original research studies, systematic reviews, case studies, and clinical trials. Currently, conventional subcutaneous immunotherapy (SCIT) is the preferred AIT in China, but sublingual immunotherapy (SLIT) is beginning to gain recognition. An increasing number of clinical trials have been conducted to investigate the clinical efficacy and side effects of SLIT and SCIT. In China, HDM is the only commercial standardized allergen extracts in clinical use, whereas the others are crude allergen extracts. Besides standardized allergen extracts, other forms of hypoallergenic extracts are still being investigated and developed in China. Immunotherapy in China is similar to that in the USA in which allergen extracts can be mixed for SCIT. However, allergen extracts cannot be mixed for SCIT in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.